Published in Clin Lipidol on October 01, 2012
Recent advances in the application of metabolomics to Alzheimer's Disease. Biochim Biophys Acta (2013) 0.92
Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease. Neurobiol Aging (2014) 0.85
Ceramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ Accumulation. Oxid Med Cell Longev (2015) 0.85
Network Analysis of a Comprehensive Knowledge Repository Reveals a Dual Role for Ceramide in Alzheimer's Disease. PLoS One (2016) 0.76
Sphingolipids in spinal cord injury. Int J Physiol Pathophysiol Pharmacol (2016) 0.75
Peripheral sphingolipids are associated with variation in white matter microstructure in older adults. Neurobiol Aging (2016) 0.75
The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer's Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging. J Alzheimers Dis (2016) 0.75
Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem (2000) 9.96
Functions of ceramide in coordinating cellular responses to stress. Science (1996) 5.54
Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature (1996) 5.48
Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res (2005) 4.24
Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 3.61
Ceramide in the eukaryotic stress response. Trends Cell Biol (2000) 2.98
Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev (2008) 2.96
Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol (2005) 2.91
GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat Med (1995) 2.77
Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem (1993) 2.77
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem (2002) 2.45
Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes (2008) 2.42
Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One (2011) 2.30
Raft ceramide in molecular medicine. Oncogene (2003) 2.20
An update of the enzymology and regulation of sphingomyelin metabolism. Biochim Biophys Acta (1990) 2.17
Vascular factors predict rate of progression in Alzheimer disease. Neurology (2007) 2.06
Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem (2005) 2.03
Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci (2010) 1.93
Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology (2012) 1.91
Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging (2008) 1.89
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol (2003) 1.78
Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet (2009) 1.77
Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol (2006) 1.73
Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem (2003) 1.73
Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease--a review. J Lipid Res (2008) 1.68
Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol (2004) 1.64
Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem (1999) 1.63
Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res (2007) 1.61
Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol (2002) 1.61
Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J (2008) 1.56
Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta (2010) 1.56
Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem (2011) 1.51
Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer patients. Neurobiol Aging (2005) 1.46
A seed for Alzheimer amyloid in the brain. J Neurosci (2004) 1.45
Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids (2006) 1.39
Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci (2004) 1.38
Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol (2012) 1.37
Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J Neurochem (1995) 1.36
Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging (2008) 1.35
Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience (2005) 1.32
Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res (2001) 1.31
Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic Biol Med (2001) 1.28
ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging (2007) 1.24
Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement (2010) 1.20
Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity. J Neurochem (1996) 1.19
Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience (1994) 1.16
BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci (2011) 1.14
Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? Neuromolecular Med (2010) 1.12
Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis (2011) 1.10
Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J Neurochem (1994) 1.07
Regulation of ceramide-induced neuronal death: cell metabolism meets neurodegeneration. Brain Res Rev (2008) 1.07
Role of gangliosides in Alzheimer's disease. Biochim Biophys Acta (2007) 1.04
Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. J Neurochem (1997) 1.02
Inhibition of glycogen synthase kinase-3β by Angelica sinensis extract decreases β-amyloid-induced neurotoxicity and tau phosphorylation in cultured cortical neurons. J Neurosci Res (2010) 0.99
Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J Alzheimers Dis (2012) 0.98
Lipids and the pathogenesis of Alzheimer's disease: is there a link? Int Rev Psychiatry (2006) 0.97
A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem (2006) 0.96
Assembly of hereditary amyloid beta-protein variants in the presence of favorable gangliosides. FEBS Lett (2005) 0.95
Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease. Neurobiol Aging (2008) 0.94
Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virus. J Neurovirol (2010) 0.92
Alzheimer peptides perturb lipid-regulating enzymes. Nat Cell Biol (2005) 0.92
Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis (2012) 0.91
Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. J Alzheimers Dis (2010) 0.91
Gangliosides determine the amyloid pathology of Alzheimer's disease. Neuroreport (2009) 0.91
Elevation of the level and activity of acid ceramidase in Alzheimer's disease brain. Eur J Neurosci (2004) 0.89
Gender-dependent accumulation of ceramides in the cerebral cortex of the APP(SL)/PS1Ki mouse model of Alzheimer's disease. Neurobiol Aging (2008) 0.85
Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease. Neurosci Lett (2012) 0.84
Cholesterol-sphingomyelin interactions in cells--effects on lipid metabolism. Subcell Biochem (1997) 0.84
Two-dimensional analysis of qualitative and quantitative changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers. Appl Theor Electrophor (1995) 0.82
Changes of mouse brain gangliosides during aging from young adult until senescence. Mech Ageing Dev (1989) 0.82
Up-regulation of glycohydrolases in Alzheimer's Disease fibroblasts correlates with Ras activation. J Biol Chem (2003) 0.82
Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer's disease patients--a pilot study. Anal Bioanal Chem (2010) 0.81
Leukocyte lysosomal enzymes in Alzheimer's disease and Down's syndrome. J Gerontol A Biol Sci Med Sci (2002) 0.79
Ceramide and Related-Sphingolipid Levels Are Not Altered in Disease-Associated Brain Regions of APP and APP/PS1 Mouse Models of Alzheimer's Disease: Relationship with the Lack of Neurodegeneration? Int J Alzheimers Dis (2010) 0.76
Presenilin 1 modifies lipid raft composition of neuronal membranes. Biochem Biophys Res Commun (2009) 0.76
Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology (2012) 1.91
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther (2002) 1.51
Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem (2009) 1.45
Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging (2008) 1.35
A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain (2008) 1.25
ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging (2007) 1.24
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement (2010) 1.20
Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis (2011) 1.10
Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice. J Neurosci Res (2010) 0.93
Role of endolysosomes in HIV-1 Tat-induced neurotoxicity. ASN Neuro (2012) 0.92
Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virus. J Neurovirol (2010) 0.92
A failure to normalize biochemical and metabolic insults during morphine withdrawal disrupts synaptic repair in mice transgenic for HIV-gp120. J Neuroimmune Pharmacol (2011) 0.91
The human immunodeficiency virus coat protein gp120 promotes forward trafficking and surface clustering of NMDA receptors in membrane microdomains. J Neurosci (2011) 0.91
Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS One (2013) 0.90
Endolysosome involvement in HIV-1 transactivator protein-induced neuronal amyloid beta production. Neurobiol Aging (2013) 0.89
The immunophilin ligand GPI1046 protects neurons from the lethal effects of the HIV-1 proteins gp120 and Tat by modulating endoplasmic reticulum calcium load. J Neurochem (2006) 0.89
Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. PLoS One (2013) 0.88
Dual effects of ATP on rat hippocampal synaptic plasticity. Neuroreport (2004) 0.87
Deficiency of a Niemann-Pick, type C1-related protein in toxoplasma is associated with multiple lipidoses and increased pathogenicity. PLoS Pathog (2011) 0.85
Adenosine triphosphate released from HIV-infected macrophages regulates glutamatergic tone and dendritic spine density on neurons. J Neuroimmune Pharmacol (2013) 0.84
Spinal cord injury causes chronic liver pathology in rats. J Neurotrauma (2014) 0.83
Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients. AIDS (2015) 0.83
Elevated plasma ceramides in depression. J Neuropsychiatry Clin Neurosci (2011) 0.82
Selected statins produce rapid spinal motor neuron loss in vitro. BMC Musculoskelet Disord (2012) 0.81
Ketone bodies protection against HIV-1 Tat-induced neurotoxicity. J Neurochem (2012) 0.80
Ceramide metabolism analysis in a model of binge drinking reveals both neuroprotective and toxic effects of ethanol. J Neurochem (2014) 0.80
Neuroprotective and antiretroviral effects of the immunophilin ligand GPI 1046. J Neuroimmune Pharmacol (2007) 0.79
GPI-1046 protects dorsal root ganglia from gp120-induced axonal injury by modulating store-operated calcium entry. J Peripher Nerv Syst (2009) 0.79
Factors affecting longitudinal trajectories of plasma sphingomyelins: the Baltimore Longitudinal Study of Aging. Aging Cell (2014) 0.78
The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids. Front Pharmacol (2012) 0.78
Interaction of paroxetine with mitochondrial proteins mediates neuroprotection. Neurotherapeutics (2015) 0.76
Ceramides predict verbal memory performance in coronary artery disease patients undertaking exercise: a prospective cohort pilot study. BMC Geriatr (2013) 0.75
Impaired long-term depression in P2X3 deficient mice is not associated with a spatial learning deficit. J Neurochem (2006) 0.75
Informatic interrogation of CSF proteomic profiles from HIV-infected subjects implicates acute phase and complement systems in shifting cognitive status. AIDS (2017) 0.75
Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients. AIDS (2017) 0.75
Inflammatory, oxidative and lipid perspectives on dementia in HIV-infected patients. Biomark Med (2007) 0.75
The Psychiatric Impact of HIV. ACS Chem Neurosci (2017) 0.75